Recombinant human erythropoietin (rhEPO) has been used clinically to alleviate cancer-and
chemotherapy-related anemia. However, recent clinical trials have reported that rhEPO also …

Erythropoietin (Epo) has long been known to be the principal hematopoietic growth factor
that regulates cellular proliferation and differentiation along the erythroid lineage. Recent …

Erythropoietin (Epo) is an essential hormone that binds and activates the Epo receptor
(EpoR) resident on the surface of erythroid progenitor cells, thereby promoting …

Recombinant human erythropoietin (rhEPO), the prototype erythropoiesis-stimulating agent
developed in the 1980s, was among the first recombinant human proteins to be marketed for …

Until 1990, erythropoietin (EPO) was considered to have a single biological purpose and
action, the stimulation of red blood cell growth and differentiation. Slowly, scientific and …

Over the past few decades, understanding of the physiologic function of erythropoietin (EPO)
has evolved significantly. EPO binds to erythropoietin receptors (EPOR), initiating signaling …

In vitro and animal model studies have shown erythropoietin receptor (Epo-R) mRNA and/or
protein may be present in a range of human tumours and cancer cell lines, and …

Safety concerns surrounding the use of recombinant human erythropoietin (Epo) to treat
anemia in cancer patients were raised after 2 recent clinical studies reported a worse …

Erythropoietin (EPO) has long been recognized as the major hematopoietic cytokine
regulating normal erythropoiesis. Moreover, there is a growing interest in the non …

Erythropoietin (Epo) therapy reduces red cell transfusion requirements and improves the
quality of life of anemic cancer patients receiving chemotherapy. However, there is concern …